Frontiers | Risk Stratification for Diffuse Large B-Cell Lymphoma by Integrating Interim Evaluation and International Prognostic Index: A Multicenter Retrospective Study
Survival analysis according to NCCN-IPI (low NCCN-IPI score < 5 and... | Download Scientific Diagram
Table 4 from An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. | Semantic Scholar
Interim 18F‑FDG PET/CT improves the prognostic value of S‑IPI, R‑IPI and NCCN‑IPI in patients with diffuse large B‑cell lymphoma
Table 1 from An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. | Semantic Scholar
The Enhanced International Prognostic Index for Diffuse Large B‐cell Lymphoma | Semantic Scholar
International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI - ScienceDirect
Optimizing Outcome Prediction in Diffuse Large B-Cell Lymphoma by Use of Machine Learning and Nationwide Lymphoma Registries: A Nordic Lymphoma Group Study | JCO Clinical Cancer Informatics
Diffuse Large B-Cell Lymphoma: Can We Improve Our Current Approaches to Management?
An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. - Abstract - Europe PMC
INDICE PRONOSTICO NCCN-IPI EN LINFOMA DIFUSO DE CELULA GRANDE (revisado 7-10-2014) - Linfomaymieloma.com
Comparison of factors and scoring of IPI, NCCN-IPI, and GELTAMO-IPI | Download Table
Prognostic indices and the risk stratification of IPI and NCCN-IPI. | Download Table
NCCN-IPI score-independent prognostic potential of pretreatment uric acid levels for clinical outcome of diffuse large B-cell lymphoma patients | British Journal of Cancer
Table 2 from An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. | Semantic Scholar
Differential Impact of Relative Dose-Intensity Reductions in Diffuse Large B-Cell Lymphoma Treated with R-CHOP21 or R-CHOP14 | PLOS ONE
Table 1 from The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. | Semantic Scholar
Validation of an enhanced International Prognostic Index (NCCN-IPI) in an Asian cohort of patients with diffuse large B cell lymphoma | SpringerLink
Improving the Prognostic Index for Diffuse Large B-Cell Lymphoma
Improving the Prognostic Index for Diffuse Large B-Cell Lymphoma
Age cutoffs for the conventional IPI, NCCN-IPI, and GELTAMO-IPI | Download Scientific Diagram
EHA Library - The official digital education library of European Hematology Association (EHA)
Validation of the International Prognostic Index and Subsequent Revisions for Diffuse Large B-Cell Lymphoma in Patients From the
Is NCCN-IPI a Better Prognostic Tool for DLBCL Treated With R-CHOP?
International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI - ScienceDirect
